aticor, formulated to help reduce
          fibrin and promote circulatory
          health, can help combat those
          dubious odds. Fibrin, on its own, is
          a good thing, as the body pro-
duces it to form blood clots. When tis-
sue damage results in bleeding, fibrino-
gen is converted at the wound into fib-
rin, which forms a mesh that dries and
hardens. Without proper enzyme bal-
ance, however, fibrin deposits can build
up in the cardiovascular system, organs
and muscle tissues. This can manifest in
many unhealthy and undesirable ail-
ments, which are worsened by the
effects of aging. To combat this prob-
lem, Naticor promotes increased fibri-
nolysis, or clot breakdown, which
facilitates healthy aging.     Bio-energy infused per Dr. Kronn’s
technology, Naticor is made up of
several  proteolytic  (protein-
digesting) enzymes, including nat-
tokinase and serrapeptase, which
are combined with R+ ipoic acid,
rutoside and a mineral matrix to
slow the formation of fibrin in the
body. NATTOKINASE Nattokinase, a potent fibrin-fight- ing  enzyme,  is  found  in  natto,  a
Japanese food produced from ferment-
ed soybeans. Naticor utilizes only the
most potent form of nattokinase, NSK-
SD. This form of Nattokinase is the most
researched and contains, per gram, the
highest activity level of any Nattokinase
available in the United States as a
dietary supplement. NSK-SD originates
from the microorganism Bacillus and is
comparatively stable in varying temper-
ature and pH. In fact, NSK-SD has been
declared a medical food. In a 2003 report entitled The Enzyme of Enzymes, Dr. Nicholas Calvino com- mented, “The magnificent thing about
nattokinase is that it appears to have
many, if not most, of the benefits of
pharmaceutical agents designed to reg- ulate  blood  clotting  (e.g.  warafin,
heparin, t-PA, urokinase, etc.) without
any of the side effects of these medica-
tions. Furthermore, while these medica-
tions have to be injected and only pro-
vide a very brief time of benefit (a few
hours), nattokinase is effective when
taken orally and its benefits linger many
times longer.”     Calvino’s report also cited other stud-
ies,   including   research   done   at
Biotechnology Research Laboratories
and JCR Pharmaceuticals Co. of Kobe,
Japan, who tested nattokinase’s ability
to dissolve a thrombus in the carotid
arteries  of rats. Animals treated with nattokinase
regained 62 percent of blood flow,
whereas those treated with plasmin
regained just 15.8 percent. Further
research from JCR Pharmaceuticals,
Oklahoma State University and Miyazaki
Medical College tested nattokinase on 6
men and 6 women between ages 21 and
55, who received 200 grams of natto
before breakfast. Fibrinolytic activity
was then tracked through a series of
blood plasma tests, which indicated the
natto generated a heightened ability to
dissolve blood clots. According to a 2002 report entitled Nattokinase and Cardiovascular Health, by Dr. Ralph E. Holsworth, Jr., a Board-
certified osteopathic family medicine
physician in Pagosa Springs, CO, nattok-
inase has many benefits including con-
venience of oral administration, con-
firmed efficacy, prolonged effects, cost-
effectiveness and its ability to be used
preventatively. The report found that
“Nattokinase may actually be superior
to conventional clot-dissolving drugs
such as recombinant tissue plasmino-
gen activators (rt-PA), urokinase and
streptokinase, which are only effective
therapeutically when taken intravenous-
ly within 12 hours of a stroke or heart
attack.” Nattokinase, Holsworth’s report con- cluded, may help prevent the condi- tions leading to blood clots with an oral daily dose of up to 2,000 fibrin     units   (FU),   or   50   grams,   of
    natto.The report added that nat-
    tokinase may prove to be a defib-
    rinogenating enzyme that drasti-
    cally decreases blood viscosity.
    This, in turn, helps prevent arte-
    riosclerosis and atherosclerosis,
    as well as hypertension, peripheral
    vascular disease and congestive
    heart failure.
In   an   interview   with   HPB,   Dr. Holsworth strongly advocated the use
of nattokinase NSK-SD. “To date,” he
says, “I’ve conducted the largest clinical
trials on NSK-SD with patients. They
showed that it decreases blood pres-
sure, both systolic and diastolic. There
was a trend showing that it decreased
blood viscosities, the thickness of the
blood, without affecting its ability to
clot. In a clinical setting, I’ve reversed
ischemic strokes with it. That was in a
hospital setting. And I’ve also dissolved
clots,  deep-veined  thrombosis,  in
patients.” Holsworth cites the findings
of Professor Hiroyuki Sumi of Japan’s
Kurashiki University of Science and the
Arts, who has said NSK-SD has the high-
est activity of all forms of nattokinase. Next Page NATICOR:Heart Care is Smart Care Naticor is made up of several proteolytic (protein-digesting) enzymes to slow the formation of fibrin in the body. Heart  disease  is  a  serious  issue  for  American  consumers.  It  has  been  reported that over 50% of all Westerners die of diseases that have an underlying cause related to arteriosclerosis, or hardening of the arteries, due to blocked arteries.